Considering both IL-7 and IFN-γ signalling in host cells are required for combination therapy-induced tumour rejection, a process dependent on T cells (Fig. 3e), we speculated that IL-7 and IFN-γ signalling in T cells dictate the immunotherapeutic benefits of combination therapy. Here, IL7 is linked to neoplasm.